Literature DB >> 8435608

Phenylketonuria due to phenylalanine hydroxylase deficiency: an unfolding story. Medical Research Council Working Party on Phenylketonuria.

.   

Abstract

Efficient neonatal screening for phenylketonuria and the availability of complex diets for lifelong use have virtually eliminated severe mental handicap from the disease. Nevertheless, there remains a high risk of fetal damage in offspring of women with the disease, and the possibility that the diets themselves may be harmful cannot be excluded. Search for a preventive treatment for the disease has been greatly aided by advances in molecular genetics. For example, in mice modified liver cells have been implanted, which have not only corrected the phenylalanine defect but have remained healthy for the normal life span of the animal. Overall, however, prevention and treatment have not progressed as quickly as was hoped, and research and development must be pursued vigorously to take account of contemporary perceptions of the disorder.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8435608      PMCID: PMC1676688          DOI: 10.1136/bmj.306.6870.115

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  35 in total

1.  Paired comparisons between early treated PKU children and their matched sibling controls on intelligence and school achievement test results at eight years of age.

Authors:  R Koch; C Azen; E G Friedman; M L Williamson
Journal:  J Inherit Metab Dis       Date:  1984       Impact factor: 4.982

2.  Early-treated phenylketonuria: neuropsychologic consequences.

Authors:  R L Brunner; M K Jordan; H K Berry
Journal:  J Pediatr       Date:  1983-06       Impact factor: 4.406

3.  Turnover of the fast components of myelin and myelin proteins in experimental hyperphenylalaninaemia. Relevance to termination of dietary treatment in human phenylketonuria.

Authors:  F A Hommes; A G Eller; E H Taylor
Journal:  J Inherit Metab Dis       Date:  1982       Impact factor: 4.982

4.  Preliminary report on the effects of diet discontinuation in PKU.

Authors:  R Koch; C G Azen; E G Friedman; M L Williamson
Journal:  J Pediatr       Date:  1982-06       Impact factor: 4.406

5.  The effects of chronic hyperphenylalaninaemia on mouse brain protein synthesis can be prevented by other amino acids.

Authors:  P Binek-Singer; T C Johnson
Journal:  Biochem J       Date:  1982-08-15       Impact factor: 3.857

6.  Effects of untreated maternal phenylketonuria and hyperphenylalaninemia on the fetus.

Authors:  H L Levy; S E Waisbren
Journal:  N Engl J Med       Date:  1983-11-24       Impact factor: 91.245

7.  Intelligence and personality characteristics in adults with untreated atypical phenylketonuria and mild hyperphenylalaninemia.

Authors:  S E Waisbren; R Schnell; H L Levy
Journal:  J Pediatr       Date:  1984-12       Impact factor: 4.406

8.  Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies.

Authors:  R R Lenke; H L Levy
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

9.  Biochemical and neuropsychological effects of elevated plasma phenylalanine in patients with treated phenylketonuria. A model for the study of phenylalanine and brain function in man.

Authors:  W Krause; M Halminski; L McDonald; P Dembure; R Salvo; D Freides; L Elsas
Journal:  J Clin Invest       Date:  1985-01       Impact factor: 14.808

10.  Enzymatic control of phenylalanine intake in phenylketonuria.

Authors:  J A Hoskins; G Jack; H E Wade; R J Peiris; E C Wright; D J Starr; J Stern
Journal:  Lancet       Date:  1980-02-23       Impact factor: 79.321

View more
  23 in total

1.  Living with phenylketonuria: perspectives of patients and their families.

Authors:  C Bilginsoy; N Waitzman; C O Leonard; S L Ernst
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

2.  Executive function in treated phenylketonuria as measured by the one-back and two-back versions of the continuous performance test.

Authors:  P Griffiths; R Campbell; P Robinson
Journal:  J Inherit Metab Dis       Date:  1998-04       Impact factor: 4.982

3.  Chaperone-like therapy with tetrahydrobiopterin in clinical trials for phenylketonuria: is genotype a predictor of response?

Authors:  Christineh N Sarkissian; Alejandra Gamez; Patrick Scott; Jerome Dauvillier; Alejandro Dorenbaum; Charles R Scriver; Raymond C Stevens
Journal:  JIMD Rep       Date:  2011-12-06

Review 4.  Sapropterin dihydrochloride for phenylketonuria.

Authors:  Usha Rani Somaraju; Marcus Merrin
Journal:  Cochrane Database Syst Rev       Date:  2015-03-27

Review 5.  Current situation and prospects of newborn screening and treatment for Phenylketonuria in China - compared with the current situation in the United States, UK and Japan.

Authors:  Lin Mei; Peipei Song; Norihiro Kokudo; Lingzhong Xu; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2013-11

Review 6.  What we know that could influence future treatment of phenylketonuria.

Authors:  C N Sarkissian; A Gámez; C R Scriver
Journal:  J Inherit Metab Dis       Date:  2008-08-03       Impact factor: 4.982

7.  Recommendations for protein and amino acid intake in phenylketonuric patients.

Authors:  F Cockburn; B J Clark
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

8.  Intellectual development of the patients of the German Collaborative Study of children treated for phenylketonuria.

Authors:  P Burgard; E Schmidt; A Rupp; W Schneider; H J Bremer
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

9.  The North American Maternal Phenylketonuria Collaborative Study, developmental assessment of the offspring: preliminary report.

Authors:  W B Hanley; R Koch; H L Levy; R Matalon; B Rouse; C Azen; F de la Cruz
Journal:  Eur J Pediatr       Date:  1996-07       Impact factor: 3.183

Review 10.  The truth of treating patients with phenylketonuria after childhood: the need for a new guideline.

Authors:  F J van Spronsen; P Burgard
Journal:  J Inherit Metab Dis       Date:  2008-08-12       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.